Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer

Cancer Management and Research
Michael R ShafiqueScott J Antonia

Abstract

Lung cancer is the most common cancer worldwide and the most common cause of cancer-related death. Non-small-cell lung cancer comprises ~87% of newly diagnosed cases of lung cancer, and nearly one-third of these patients have stage III disease. Despite improvements in the treatment of stage IV lung cancer, particularly with the introduction and dissemination of checkpoint inhibitors, very little progress has been made in the treatment of stage III lung cancer. In this article, we discuss the general staging criteria and treatment options for stage III lung cancer. We review how concurrent radiation and chemotherapy can have immunomodulatory effects, supporting the rationale for incorporating immunotherapy into existing treatment paradigms. Finally, we discuss the results of the PACIFIC trial and implications for the treatment of stage III lung cancer. In the PACIFIC trial, adding durvalumab as a maintenance therapy following the completion of chemoradiotherapy improved progression-free survival in patients with locally advanced unresectable stage III lung cancer. On the strength of these results, durvalumab has been approved by the US Food and Drug Administration for use in this setting, representing the first advance in the tr...Continue Reading

Citations

Mar 2, 2021·Expert Opinion on Investigational Drugs·Alessandro RizzoGiovanni Brandi
Jan 24, 2020·Current Drug Targets·Francesca GiunchiMichelangelo Fiorentino
Jun 1, 2021·Frontiers in Oncology·Xinyi HuangJiandong Zhang

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection

Clinical Trials Mentioned

NCT02768558
NCT02434081
NCT02987998
NCT00828009
NCT02662634

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

The New England Journal of Medicine
Naiyer A Rizvi, Solange Peters
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Young Hak Kim, Michiaki Mishima
The New England Journal of Medicine
Matteo SantoniSebastiano Buti
The New England Journal of Medicine
Scott J Antonia, Mustafa Özgüroğlu
© 2022 Meta ULC. All rights reserved